Jaguar Health's Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company's Focus on Rare Diseases & Orphan Drugs

Stock Information for Jaguar Health Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Jaguar Health Inc.

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
Jaguar Health Reports 2023 Financial Results
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.